What Is New in Small Cell Lung Cancer

Robert Matera; Anne Chiang

doi:10.1016/j.hoc.2023.02.010

What Is New in Small Cell Lung Cancer

Hematol Oncol Clin North Am. 2023 Jun;37(3):595-607. doi: 10.1016/j.hoc.2023.02.010. Epub 2023 Apr 4.

Authors

Robert Matera¹, Anne Chiang²

Affiliations

¹ Department of Hematology and Oncology, Yale New Haven Hospital, 20 York Street, New Haven, CT, USA. Electronic address: robert.matera@yale.edu.
² Department of Hematology and Oncology, Yale New Haven Hospital, 20 York Street, New Haven, CT, USA.

PMID: 37024387
DOI: 10.1016/j.hoc.2023.02.010

Abstract

Small cell lung cancer (SCLC) is a rare yet aggressive lung cancer subtype with an extremely poor prognosis of around 1 year. SCLC accounts for 15% of all newly diagnosed lung cancers and is characterized by rapid growth with high potential for metastatic spread and treatment resistance. In the article the authors review some of the most notable efforts to improve outcomes, including trials of novel immunotherapy agents, novel disease targets, and multiple drug combinations.

Keywords: Drug; Immunotherapy; Radiation; Small cell lung cancer.

Publication types

Review

MeSH terms

Humans
Immunologic Factors / therapeutic use
Immunotherapy
Lung Neoplasms* / therapy
Prognosis
Small Cell Lung Carcinoma* / drug therapy
Small Cell Lung Carcinoma* / pathology

Substances

Immunologic Factors